For the quarter ending 2025-09-30, FDMT had -$28,604K decrease in cash & cash equivalents over the period. -$46,407K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -56,876 | -102,630 |
| Stock-based compensation expense | 4,519 | 11,944 |
| Change in fair value of derivative liability | 11 | -76 |
| Depreciation and amortization | 1,261 | 2,217 |
| Amortization of right-of-use assets | 742 | 1,425 |
| Net accretion of discount on marketable securities | 1,154 | 2,433 |
| Prepaid expenses and other current assets | -2,748 | 7 |
| Other assets | -10 | 5,129 |
| Accounts payable | -1,837 | 4,314 |
| Accrued and other liabilities | 4,982 | 798 |
| Deferred revenue | -90 | -29 |
| Operating lease liabilities | -814 | -1,529 |
| Net cash used in operating activities | -46,498 | -91,135 |
| Purchase of marketable securities | 15,241 | 249,480 |
| Maturities of marketable securities | 32,928 | 268,273 |
| Acquisition of property and equipment | -91 | 697 |
| Net cash provided by (used in) investing activities | 17,778 | 18,096 |
| Issuance of common stock upon exercise of stock options and warrants | 116 | 2 |
| Issuance of common stock - 2020 espp | 0 | 860 |
| Net cash provided by financing activities | 116 | 862 |
| Net decrease in cash and cash equivalents | -28,604 | -72,177 |
| Cash and cash equivalents at beginning of period | 149,336 | - |
| Cash and cash equivalents at end of period | 48,555 | - |
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)